Jonathan Gardner on Muck Rack

Jonathan Gardner

Verified
Charlottesville
As seen in: BioPharma Dive, Yahoo Finance, Flipboard, Yahoo, NewsBreak, Healthcare Dive, MDEdge, Supply Chain Dive, Yahoo Finanzas, HR Dive, K-12 Dive and
Senior reporter, BioPharma Dive. Father of 1, husband of 1, son of 2, brother of 2, uncle of 7. Opinions are mine. RTs are not endorsements. Darn good runner.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jonathan

Contact Jonathan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Summit pulls $500M share sale a day after announcing it Original

|
By Jonathan Gardner 
| BioPharma Dive
Dive Brief: Summit Therapeutics, developer of a leading experimental lung cancer drug, on Wednesday pulled plans for a $500 million secondary share offering it announced a day before, citing “market conditions.” The proposed offering came nine days after Summit’s partner Akeso detailed positive data from a China-based Phase 3 lung cancer trial of an experimental drug, “ivonescimab,” they are developing together.
Open in Who Shared View Duplicates (2) Issue with article?

Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test Original

|
By Jonathan Gardner 
| BioPharma Dive
Dive Brief: Takeda’s experimental autoimmune drug zasocitinib bested Bristol Myers Squibb’s marketed medicine Sotyktu in a head-to-head study in psoriasis, the company said Thursday. Takeda didn’t provide detailed data, but said that zasocitinib demonstrated statistical superiority against Sotyktu on all main and secondary study goals. After 16 weeks, zasocitinib helped completely eliminate the skin lesions in over a third of recipients, more than doubling what was seen with Sotyktu.
Open in Who Shared View Duplicates (2) Issue with article?

Don’t miss tomorrow’s biopharma industry news Original

|
By Jonathan Gardner, Jonathan Gardner 
| BioPharma Dive
Dive Brief: An experimental treatment from Veradermics hit the main goal of a Phase 3 trial, helping people with male pattern baldness grow significantly more new hair over six months than those who got a placebo. If approved by regulators, the therapy, an extended-release, oral formulation of the topical treatment minoxidil, could become the first new marketed pill for baldness in 30 years.
Open in Who Shared View Duplicates (2) Issue with article?
See all 1,602 articles

Actions

Share this page

Get in touch with Jonathan

Contact Jonathan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified